I'm not emotional over this. You don't know if pharma is ready to commit anything to a MANF partnership or not. There can be interest and financial offers, which the company can decline, as they have with LymPro. The company is not obligated to report the offers made, only the ones they accept. You are making an assumption that because no big pharma partnership has been announced, they aren't ready to commit financial resources. That assumption has already been proven false with LymPro. Therefore it is an invalid assumption for MANF.

I wasn't aware I was "attacking" your view. I was offering an alternate scenario based on what's happened with LymPro. Sounds like someone beside me needs to chill the heck out and not read things into press releases based on flawed assumptions.